Oruka Therapeutics Inc (ORKA)
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody therapies for psoriasis and other inflammatory and immunology-related conditions. The company’s pipeline includes ORKA-001, a Phase 2a candidate designed to target the p19 subunit of interleukin-23 for psoriasis, and ORKA-002, a Phase 2 candidate aimed at interleukin-17A and interleukin-17F for psoriasis, psoriatic arthritis, and additional indications. Oruka is also advancing ORKA-003, which is being developed against an undisclosed pathway, along with ORKA-021, a sequential combination regimen involving ORKA-002 and ORKA-001. The company is headquartered in Menlo Park, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ORKA
|
$53.64
|
-43.3% Downside
|
Overvalued
|
$148.17
|
56.7% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-60.9x
|
11.8x
|
—
|
5.531 B
|
5.241 B
|
0.0%
|
84.7%
|
186.3
|
—
|
96.8%
|
